Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,363 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Regulatory
402 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Sotorasib | EU EMA | Lung Non-Small Cell Carcinoma | Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.conditional | approved | Jan 6, 2022 | ema |
| Sugemalimab | EU EMA | Lung Non-Small Cell Carcinoma | Cejemly in combination with platinum-based chemotherapy is indicated for the first line treatment of adults with metastatic non small cell lung cancer (NSCLC) with no sensitising EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations. Cejemly as monotherapy is indicated for the treatment of unresectable stage III NSCLC with no sensitising EGFR mutations, or ALK, ROS1 genomic tumour aberrations in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiotherapy. | approved | Jul 24, 2024 | ema |
| Tarlatamab | EU EMA | Lung Small Cell Carcinoma | Imdylltra is indicated as monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy. | approved | May 29, 2026 | ema |
| Temoporfin | EU EMA | Head and Neck Squamous Cell Carcinoma | Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy. | approved | Oct 24, 2001 | ema |
| Tepotinib | EU EMA | Lung Non-Small Cell Carcinoma | Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. | approved | Feb 16, 2022 | ema |
| Thyrotropin Alfa | EU EMA | Differentiated Thyroid Gland Carcinoma | Thyrogen is indicated for use with serum thyroglobulin (Tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (THST). Low risk patients with well-differentiated thyroid carcinoma who have undetectable serum Tg levels on THST and no rh (recombinant human) TSH-stimulated increase of Tg levels may be followed-up by assaying rh TSH-stimulated Tg levels. Thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mCi (1.1 GBq) to 100 mCi (3.7 GBq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.4). | approved | Mar 9, 2000 | ema |
| Tivozanib | EU EMA | Renal Cell Carcinoma | Fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. Treatment of advanced renal cell carcinoma. | approved | Aug 24, 2017 | ema |
| Topotecan | EU EMA | Cervical Carcinoma | Topotecan monotherapy is indicated for the treatment of:- patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy- patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1). Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.1). | approved | Jan 6, 2011 | ema |
| Topotecan | EU EMA | Ovarian Carcinoma | Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. | withdrawn | Apr 15, 1997 | ema |
| Trastuzumab | EU EMA | Early Stage Breast Carcinoma | Early breast cancer (EBC) Phesgo is indicated for use in combination with chemotherapy in: the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence Metastatic breast cancer (MBC) Phesgo is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. | approved | Dec 21, 2020 | ema |
| Tremelimumab | EU EMA | Lung Non-Small Cell Carcinoma | Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations. | withdrawn | Feb 20, 2023 | ema |
| Vandetanib | EU EMA | Thyroid Gland Medullary Carcinoma | Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older. For patients in whom re-arranged-during-transfection(RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision. | approved | Feb 16, 2012 | ema |
| Vinflunine | EU EMA | Urothelial Carcinoma | Javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional-cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen. Efficacy and safety of vinflunine have not been studied in patients with performance status ? 2. | approved | Sep 21, 2009 | ema |
| Vismodegib | EU EMA | Basal Cell Carcinoma | Erivedge is indicated for the treatment of adult patients with:- symptomatic metastatic basal cell carcinoma- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy | approved | Jul 12, 2013 | ema |
Data updated 14 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Erlotinib | 219 | 139 | 80 |
| Crizotinib | 175 | 86 | 89 |
| Gefitinib | 151 | 126 | 25 |
| Afatinib | 106 | 99 | 7 |
| Trastuzumab | 75 | 50 | 25 |
| Osimertinib | 53 | 39 | 14 |
| Cisplatin | 42 | 31 | 10 |
| Trametinib | 39 | 36 | 3 |
| Vemurafenib | 38 | 23 | 15 |
| Erdafitinib | 37 | 35 | 2 |
| Lapatinib | 36 | 24 | 12 |
| Olaparib | 36 | 34 | 2 |
| Cetuximab | 33 |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 26 |
| 6 |
| Vismodegib | 29 | 5 | 24 |
| Pembrolizumab | 28 | 24 | 4 |
| Chemotherapy | 27 | 26 | 1 |
| Futibatinib | 27 | 25 | 2 |
| Gemcitabine | 27 | 21 | 5 |
| Infigratinib | 26 | 23 | 3 |
| Ceritinib | 25 | 20 | 5 |
| Everolimus | 25 | 21 | 4 |
| Selpercatinib | 25 | 19 | 6 |
| Dabrafenib | 23 | 22 | 1 |
| Trastuzumab Deruxtecan | 23 | 23 | 0 |
| Alectinib | 20 | 13 | 7 |
| Sorafenib | 20 | 17 | 3 |
| Carboplatin | 19 | 17 | 2 |
| Dactolisib | 19 | 11 | 8 |
| Selumetinib | 18 | 16 | 2 |
| Docetaxel | 17 | 11 | 6 |
| Neratinib | 17 | 17 | 0 |
| Paclitaxel | 17 | 10 | 6 |
| Trastuzumab Emtansine | 17 | 8 | 9 |
| Dasatinib | 16 | 15 | 1 |
| PI103 | 16 | 16 | 0 |
| Atezolizumab | 15 | 13 | 2 |
| Capmatinib | 15 | 13 | 1 |
| Dacomitinib | 14 | 13 | 1 |
| Lorlatinib | 14 | 11 | 3 |
| Palbociclib | 14 | 13 | 1 |
| Pemetrexed | 14 | 10 | 4 |
| Tepotinib | 14 | 14 | 0 |
| Cabozantinib | 13 | 12 | 1 |
| Larotrectinib | 13 | 12 | 1 |
| Pazopanib | 13 | 12 | 1 |
| Sotorasib | 13 | 13 | 0 |
| Entrectinib | 12 | 10 | 2 |
| Platinum Compound | 12 | 11 | 1 |
| Pertuzumab | 11 | 11 | 0 |
| Pictilisib | 11 | 11 | 0 |
| Sirolimus | 11 | 11 | 0 |
| Sunitinib | 11 | 8 | 2 |
| Durvalumab | 10 | 9 | 1 |
| Immune Checkpoint Inhibitor | 10 | 8 | 1 |
| Nivolumab | 10 | 8 | 2 |
| Brigatinib | 9 | 8 | 1 |
| Fluorouracil | 9 | 8 | 1 |
| PD173074 | 9 | 9 | 0 |
| Talazoparib | 9 | 9 | 0 |
| Bevacizumab | 8 | 7 | 1 |
| Enzalutamide | 7 | 7 | 0 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 7 | 5 | 2 |
| Sunvozertinib | 7 | 7 | 0 |
| Vandetanib | 7 | 6 | 1 |
| ALK Inhibitor TAE684 | 6 | 4 | 2 |
| Capecitabine | 6 | 5 | 1 |
| Fexagratinib | 6 | 6 | 0 |
| Foretinib | 6 | 5 | 1 |
| Imatinib | 6 | 6 | 0 |
| Panitumumab | 6 | 4 | 2 |
| Taselisib | 6 | 5 | 1 |
| Alpelisib | 5 | 4 | 1 |
| Amivantamab | 5 | 5 | 0 |
| Dovitinib | 5 | 5 | 0 |
| Imatinib Mesylate | 5 | 5 | 0 |
| MEK Inhibitor CI-1040 | 5 | 5 | 0 |
| Radiation Therapy | 5 | 3 | 2 |
| Rociletinib | 5 | 4 | 1 |
| Rucaparib | 5 | 5 | 0 |
| Sapanisertib | 5 | 5 | 0 |
| SU11274 | 5 | 5 | 0 |
| Abemaciclib | 4 | 4 | 0 |
| Akt Inhibitor MK2206 | 4 | 4 | 0 |
| Icotinib | 4 | 3 | 1 |
| Ipilimumab/Nivolumab Regimen | 4 | 4 | 0 |
| MTOR Inhibitor | 4 | 4 | 0 |
| Niraparib | 4 | 4 | 0 |
| PD1 Inhibitor | 4 | 3 | 1 |
| PI3Ka/Di | 4 | 3 | 1 |
| Ponatinib | 4 | 4 | 0 |
| Pralsetinib | 4 | 1 | 3 |
| Repotrectinib | 4 | 4 | 0 |
| Ruxolitinib | 4 | 4 | 0 |
| Vistusertib | 4 | 4 | 0 |
| Alisertib | 3 | 3 | 0 |
| Alvespimycin | 3 | 3 | 0 |
| Anti-PD1 Monoclonal Antibody | 3 | 2 | 1 |
| Anti-VEGF Monoclonal Antibody | 3 | 2 | 1 |
| ARS-1620 | 3 | 3 | 0 |
| Avelumab | 3 | 2 | 1 |
| AZD-4547 | 3 | 3 | 0 |
| Capivasertib | 3 | 3 | 0 |
| Cisplatin/Pembrolizumab/Pemetrexed Regimen | 3 | 0 | 3 |
| Dabrafenib/Trametinib Regimen | 3 | 3 | 0 |
| Deguelin | 3 | 3 | 0 |
| EAP Protocol | 3 | 3 | 0 |
| Ensartinib | 3 | 3 | 0 |
| Etoposide | 3 | 3 | 0 |
| Fulvestrant | 3 | 2 | 1 |
| Irinotecan | 3 | 3 | 0 |
| Ivosidenib | 3 | 3 | 0 |
| Lazertinib | 3 | 3 | 0 |
| Lenvatinib | 3 | 2 | 1 |
| Mitomycin | 3 | 2 | 1 |
| Oxaliplatin | 3 | 1 | 2 |
| PI-103 | 3 | 3 | 0 |
| PI3Kbeta Inhibitor AZD8186 | 3 | 3 | 0 |
| Poziotinib | 3 | 3 | 0 |
| Ramucirumab | 3 | 2 | 1 |
| Sonidegib | 3 | 2 | 1 |
| Temsirolimus | 3 | 3 | 0 |
| Vinorelbine | 3 | 3 | 0 |
| Zongertinib | 3 | 3 | 0 |
| Adagrasib | 2 | 2 | 0 |
| Adjuvant Chemotherapy | 2 | 2 | 0 |
| Anti-PD-1 Monoclonal Antibody MEDI0680 | 2 | 2 | 0 |
| Anti-PD-L1 Monoclonal Antibody | 2 | 1 | 1 |
| Aspirin | 2 | 2 | 0 |
| Aumolertinib | 2 | 1 | 1 |
| Axitinib | 2 | 0 | 2 |
| B-Raf/VEGFR-2 Inhibitor RAF265 | 2 | 2 | 0 |
| Camonsertib | 2 | 2 | 0 |
| Canertinib | 2 | 2 | 0 |
| Carboplatin/Paclitaxel Regimen | 2 | 2 | 0 |
| Carboplatin/Pemetrexed Regimen | 2 | 2 | 0 |
| Checkpoint Kinase Inhibitor AZD7762 | 2 | 2 | 0 |
| Derazantinib | 2 | 2 | 0 |
| Dinaciclib | 2 | 2 | 0 |
| Doxorubicin | 2 | 1 | 1 |
| Durvalumab/Tremelimumab Regimen | 2 | 2 | 0 |
| Firmonertinib | 2 | 2 | 0 |
| Imlunestrant Regimen | 2 | 2 | 0 |
| Immunotherapy | 2 | 2 | 0 |
| Ipilimumab | 2 | 2 | 0 |
| Irbesartan | 2 | 2 | 0 |
| JQ1 | 2 | 2 | 0 |
| JSI-124 | 2 | 2 | 0 |
| KRAS G12D Inhibitor HRS-4642 | 2 | 2 | 0 |
| Leucovorin | 2 | 2 | 0 |
| Lunresertib | 2 | 2 | 0 |
| Metformin | 2 | 2 | 0 |
| Mitogen-Activated Protein Kinase Kinase Inhibitor | 2 | 1 | 1 |
| Mobocertinib | 2 | 2 | 0 |
| Motesanib | 2 | 0 | 2 |
| Nab-paclitaxel | 2 | 1 | 1 |
| NSC84167 | 2 | 2 | 0 |
| Palbociclib Regimen | 2 | 2 | 0 |
| Panobinostat | 2 | 2 | 0 |
| Pan-RAF/MEK Molecular Glue NST-628 | 2 | 2 | 0 |
| Pemigatinib | 2 | 1 | 1 |
| Prexasertib | 2 | 2 | 0 |
| Regorafenib Anhydrous | 2 | 2 | 0 |
| Retaspimycin Hydrochloride | 2 | 2 | 0 |
| Ribociclib | 2 | 2 | 0 |
| Rovalpituzumab Tesirine | 2 | 2 | 0 |
| Sacituzumab Govitecan | 2 | 0 | 2 |
| Savolitinib | 2 | 1 | 1 |
| Setidegrasib | 2 | 2 | 0 |
| Sevabertinib | 2 | 2 | 0 |
| Sintilimab | 2 | 2 | 0 |
| Sulindac | 2 | 2 | 0 |
| Taletrectinib | 2 | 2 | 0 |
| Tanespimycin | 2 | 2 | 0 |
| Tipifarnib | 2 | 2 | 0 |
| Tremelimumab | 2 | 2 | 0 |
| Zenocutuzumab-zbco | 2 | 2 | 0 |
| Zolbetuximab | 2 | 2 | 0 |
| 2,4-pyrimidinediamine | 1 | 1 | 0 |
| 2-Deoxy-D-glucose | 1 | 1 | 0 |
| 7-Ethyl-10-Hydroxycamptothecin | 1 | 1 | 0 |
| 9F7-F11 | 1 | 1 | 0 |
| A66 | 1 | 1 | 0 |
| Abemaciclib Regimen | 1 | 1 | 0 |
| Abexinostat | 1 | 1 | 0 |
| Abiraterone | 1 | 1 | 0 |
| Adavosertib | 1 | 1 | 0 |
| Adebrelimab | 1 | 1 | 0 |
| Ado-trastuzumab Emtansine Regimen | 1 | 1 | 0 |
| AMG511 | 1 | 1 | 0 |
| Anti-CTLA-4 Monoclonal Antibody | 1 | 1 | 0 |
| Antigen-specific Cytotoxic T-lymphocyte Therapy | 1 | 1 | 0 |
| Anti-PDL1 Therapy | 1 | 1 | 0 |
| Anti-TIM-3 Monoclonal Antibody | 1 | 1 | 0 |
| Apitolisib | 1 | 1 | 0 |
| Aromatase Inhibitor | 1 | 1 | 0 |
| Arsenic Trioxide | 1 | 1 | 0 |
| ATR Inhibitor | 1 | 1 | 0 |
| AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M | 1 | 1 | 0 |
| AZD3463 | 1 | 0 | 1 |
| Barasertib | 1 | 1 | 0 |
| Bazedoxifene | 1 | 1 | 0 |
| Befotertinib | 1 | 1 | 0 |
| Bicalutamide | 1 | 0 | 1 |
| Bimiralisib | 1 | 1 | 0 |
| Birabresib | 1 | 1 | 0 |
| BMVC-8C3O | 1 | 1 | 0 |
| Bortezomib | 1 | 1 | 0 |
| Bosutinib | 1 | 1 | 0 |
| C646 | 1 | 1 | 0 |
| Camrelizumab | 1 | 1 | 0 |
| CAPOX Regimen | 1 | 1 | 0 |
| Carboplatin OR Cisplatin | 1 | 0 | 1 |
| C-DIM 12 | 1 | 0 | 1 |
| Celecoxib | 1 | 1 | 0 |
| CH6953755 | 1 | 1 | 0 |
| Chemoimmunotherapy | 1 | 0 | 1 |
| Chemoradiotherapy | 1 | 0 | 1 |
| Copanlisib | 1 | 1 | 0 |
| CTLA-4 Inhibitor | 1 | 1 | 0 |
| Dacomitinib | 1 | 1 | 0 |
| Datopotamab Deruxtecan | 1 | 1 | 0 |
| Datopotamab Deruxtecan Regimen | 1 | 1 | 0 |
| Divarasib | 1 | 1 | 0 |
| Dostarlimab | 1 | 1 | 0 |
| DS-6501b | 1 | 1 | 0 |
| Durvalumab Regimen | 1 | 1 | 0 |
| EGFR Tyrosine Kinase Inhibitor Therapy | 1 | 1 | 0 |
| Enzastaurin | 1 | 1 | 0 |
| Eribulin | 1 | 1 | 0 |
| Erlotinib Hydrochloride | 1 | 1 | 0 |
| Fadraciclib | 1 | 1 | 0 |
| Fasudil | 1 | 1 | 0 |
| FGFR4 Inhibitor H3B-6527 | 1 | 1 | 0 |
| FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 | 1 | 1 | 0 |
| Fisogatinib | 1 | 1 | 0 |
| FOLFOX-6 Regimen | 1 | 1 | 0 |
| Ganetespib | 1 | 1 | 0 |
| Ganitumab | 1 | 1 | 0 |
| G-Quadruplex Stabilizer BMVC | 1 | 1 | 0 |
| Ibrutinib | 1 | 1 | 0 |
| Ibuprofen | 1 | 1 | 0 |
| ICX-101 | 1 | 1 | 0 |
| Idelalisib | 1 | 1 | 0 |
| Iodine I-131 | 1 | 0 | 1 |
| JAK2 Inhibitor AZD1480 | 1 | 1 | 0 |
| JNJ38877605 | 1 | 0 | 1 |
| JW55 | 1 | 1 | 0 |
| Lestaurtinib | 1 | 1 | 0 |
| Linsitinib | 1 | 1 | 0 |
| Luminespib | 1 | 0 | 1 |
| Lumretuzumab | 1 | 1 | 0 |
| MEK Inhibitor RO4987655 | 1 | 0 | 1 |
| Mirdametinib | 1 | 1 | 0 |
| Molibresib | 1 | 1 | 0 |
| MTOR Kinase Inhibitor AZD8055 | 1 | 1 | 0 |
| MUC1-targeted Peptide GO-203-2C | 1 | 0 | 1 |
| Naquotinib | 1 | 0 | 1 |
| Nedaplatin | 1 | 0 | 1 |
| Nilotinib | 1 | 1 | 0 |
| Nimotuzumab | 1 | 1 | 0 |
| Nintedanib | 1 | 1 | 0 |
| NVP-AST487 | 1 | 1 | 0 |
| Onartuzumab | 1 | 1 | 0 |
| Onatasertib | 1 | 1 | 0 |
| Osimertinib Mesylate | 1 | 1 | 0 |
| Paclitaxel Liposome | 1 | 1 | 0 |
| Palliative Radiation Therapy | 1 | 0 | 1 |
| Pan-AKT Kinase Inhibitor GSK690693 | 1 | 1 | 0 |
| Patritumab | 1 | 1 | 0 |
| PD-1 Ligand Inhibitor | 1 | 1 | 0 |
| PD-L1 Inhibitor | 1 | 1 | 0 |
| Pembrolizumab/Pemetrexed Regimen | 1 | 1 | 0 |
| Pertuzumab/Trastuzumab Regimen | 1 | 0 | 1 |
| PHA-665752 | 1 | 0 | 1 |
| PI3K/BET Inhibitor LY294002 | 1 | 1 | 0 |
| Pilaralisib | 1 | 1 | 0 |
| Platinum Doublet | 1 | 0 | 1 |
| Porcupine Inhibitor WNT974 | 1 | 1 | 0 |
| PSI | 1 | 1 | 0 |
| Pyrotinib | 1 | 1 | 0 |
| R3Mab | 1 | 0 | 1 |
| Radioactive Iodine | 1 | 1 | 0 |
| Raltitrexed | 1 | 0 | 1 |
| Refametinib | 1 | 1 | 0 |
| Regorafenib | 1 | 1 | 0 |
| Rilotumumab | 1 | 1 | 0 |
| RMC-4550 | 1 | 1 | 0 |
| Roflumilast | 1 | 1 | 0 |
| Salirasib | 1 | 1 | 0 |
| SCH772984 | 1 | 1 | 0 |
| Selective Estrogen Receptor Covalent Antagonist H3B-6545 | 1 | 1 | 0 |
| SHP2 Inhibitor | 1 | 1 | 0 |
| Stattic | 1 | 1 | 0 |
| Staurosporine | 1 | 1 | 0 |
| TAK-788 | 1 | 1 | 0 |
| Tarextumab | 1 | 1 | 0 |
| Tarloxotinib | 1 | 1 | 0 |
| Taxane Compound | 1 | 1 | 0 |
| Temozolomide | 1 | 1 | 0 |
| Teprotumumab | 1 | 1 | 0 |
| Tgx 221 | 1 | 1 | 0 |
| TGX221 | 1 | 1 | 0 |
| Tislelizumab | 1 | 1 | 0 |
| Tizaterkib | 1 | 1 | 0 |
| Toripalimab | 1 | 1 | 0 |
| Tozasertib | 1 | 1 | 0 |
| Tretinoin | 1 | 1 | 0 |
| Tyrosine Kinase Inhibitor SU5402 | 1 | 1 | 0 |
| UO126 | 1 | 1 | 0 |
| Volasertib | 1 | 1 | 0 |
| Vorinostat | 1 | 1 | 0 |
| WHI-P154 | 1 | 1 | 0 |
| WRN Inhibitor HRO761 | 1 | 1 | 0 |
| WRN Inhibitor RO7589831 | 1 | 1 | 0 |
| WZ4002 | 1 | 0 | 1 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.